Clinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility [0.03%]
用于白血病患者的临床验证：通过评估全血至血浆转换策略和自我微量采样可行性来验证Venclyxto体积微取样的有效性
A D Levens,J Rijstenbil,E Metscher et al.
A D Levens et al.
Background and objective: Venetoclax shows substantial pharmacokinetic (PK) variability and frequent toxicity, making it an archetypal candidate for PK monitoring. Capillary microsampling may facilitate decentralized PK m...
Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty [0.03%]
GenSci006（3.75毫克醋酸曲普瑞林微球）儿科外推人群药代动力学：中枢性早熟患儿
Kun Wang,Zhongyi Sun,Fengyan Xu et al.
Kun Wang et al.
Background and objectives: Triptorelin acetate microspheres are long-acting gonadotropin-releasing hormone (GnRH) agonist used for treating central precocious puberty (CPP). GenSci006 is a newly developed 3.75-mg formulat...
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease [0.03%]
为什么测定方法在基于模型的精准给药中至关重要？以溃疡性结肠炎中的乌司奴单抗为例
Wei Zhang,Zhigang Wang,Thierry Dervieux et al.
Wei Zhang et al.
Background and objective: Systematic bias between therapeutic drug monitoring assays may lead to inappropriate treatment decisions in clinical practice. While such bias is well recognized, its impact on model-informed pre...
Exposure-Response Relationships of Antibody Drug Conjugates in Solid Tumours [0.03%]
抗体药物偶联物在实体瘤中的暴露反应关系
Merel J J Lucassen,Pauline L M Buitelaar,Bart A W Jacobs et al.
Merel J J Lucassen et al.
Over the last decade, there has been an increase in development of antibody drug conjugates (ADCs), a drug class designed to bring chemotherapeutic agents to tumour sites. The pharmacokinetics of ADCs are complex, due to their multifaceted ...
Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve [0.03%]
采用标准暴露评估指标和部分面积下方面积进行抗新型冠状病毒药物替沙格韦单抗和西加韦单抗菌药动力学比对研究
Huixia Zhang,Weifeng Tang,Samuel Sadow et al.
Huixia Zhang et al.
Background and objective: AZD7442 is a combination of extended half-life monoclonal antibodies (mAbs; tixagevimab and cilgavimab), developed to neutralize SARS-CoV-2. This open-label Phase 1 study compared pharmacokinetic...
Optimising Paediatric Medication Adherence Through Innovative Drug Formulations and Delivery Systems [0.03%]
通过创新药物配方和输送系统优化儿科用药依从性
Nokwanda Nhlanzeko Ngcobo
Nokwanda Nhlanzeko Ngcobo
Medication adherence remains a significant challenge in healthcare, particularly in paediatric populations, where non-adherence has a substantial impact on therapeutic outcomes and contributes to increased healthcare costs. This manuscript ...
Population Pharmacokinetic Modelling of Unbound Mycophenolic Acid and its Glucuronide in Adult Kidney Transplant Recipients in Early Post-Transplant [0.03%]
肾移植受者早期移植物排斥反应中霉酚酸和葡萄糖醛酸结合物非限定状态药动学群体研究
Yan Rong,Ala&#x;A Al-Dajani,Jinal Adhiya et al.
Yan Rong et al.
Background and objective: The first-line immunosuppressant mycophenolic acid (MPA) is characterised by complex, variable pharmacokinetics (PK) with high protein binding, where the relationship between total and unbound dr...
Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants [0.03%]
健康参与者中强CYP3A4诱导剂苯妥英对阿斯科明禁200毫克药代动力学的影响
Matthias Hoch,Amanda J Taylor,Felix Huth et al.
Matthias Hoch et al.
Background and objectives: Asciminib is indicated for the treatment of adult patients with newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) at a...
Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva [0.03%]
单份唾液样本利奈唑胺多药耐药结核病给药方案：血浆和唾液群体药代动力学模型研究
Thi A Nguyen,Tri P Nguyen,Anh T Nguyen et al.
Thi A Nguyen et al.
Background and objective: Therapeutic drug monitoring (TDM) of linezolid for treating multidrug-resistant tuberculosis (MDR-TB) is recommended but is hindered by the invasive and logistical challenges of plasma sampling. ...
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness [0.03%]
纠正：基于模型的替代给药策略以改善皮下纳武单抗注射的性价比
Yan Wang,Laura H Bukkems,Rob Ter Heine et al.
Yan Wang et al.
Published Erratum
Clinical pharmacokinetics. 2026 Mar 12. DOI:10.1007/s40262-026-01627-3 2026